Nurix Therapeutics (NASDAQ:NRIX) Issues Quarterly Earnings Results

Nurix Therapeutics (NASDAQ:NRIX) posted its quarterly earnings results on Thursday. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08), Yahoo Finance reports. The business had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $19.35 million. Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 82.08%.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $23.82 on Friday. The stock’s 50 day moving average price is $17.32 and its 200 day moving average price is $13.62. Nurix Therapeutics has a one year low of $4.22 and a one year high of $23.99.

Analysts Set New Price Targets

Several analysts have commented on NRIX shares. Royal Bank of Canada lifted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Friday. JPMorgan Chase & Co. lifted their price target on Nurix Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, June 17th. HC Wainwright lifted their price target on Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, June 18th. Needham & Company LLC reduced their price objective on Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $35.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Insider Buying and Selling

In related news, insider Christine Ring sold 5,760 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $20.81, for a total transaction of $119,865.60. Following the transaction, the insider now directly owns 19,838 shares of the company’s stock, valued at approximately $412,828.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,499 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.83, for a total value of $44,892.17. Following the transaction, the chief financial officer now directly owns 68,333 shares of the company’s stock, valued at approximately $876,712.39. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Christine Ring sold 5,760 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $20.81, for a total value of $119,865.60. Following the completion of the transaction, the insider now directly owns 19,838 shares in the company, valued at $412,828.78. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,549 shares of company stock valued at $271,888. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.